Internal Medicine, Endocrinology, Diabetes, & Metabolism · Wichita, KS
NPI
1952523276
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3161 N Webb Rd Ste 200
Wichita, KS, 67226
Phone (316) 350-5455
Groups this clinician bills Medicare through
Medicare paid, 2024
$103K
30,209 services
Medicare patients, 2024
767
Average age 72
Drug cost, 2024
$2.6M
6,905 prescriptions
Company payments, 2025
$154K
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dany H Zayour was code J1071 (injection, testosterone cypionate, 1 mg), 28,629 times for 12 patients. In total Dany H Zayour billed 30,209 services in 13 codes, and Medicare paid $103K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1071 Injection, testosterone cypionate, 1 mg | Office | 28,629 | 12 | $0.02 | $468 |
| 99214 Office E&M - Established | Office | 644 | 425 | $80.27 | $52K |
| 99213 Office E&M - Established | Office | 314 | 266 | $57.69 | $18K |
| 96372 Injection Administration | Office | 237 | 53 | $9.52 | $2,256 |
| 99204 Office E&M - New | Office | 183 | 183 | $108.53 | $20K |
| 76536 Ultrasound - Nonspecific | Office | 58 | 53 | $67.87 | $3,936 |
| 10005 Other Organ Systems | Office | 45 | 44 | $92.18 | $4,148 |
| 95251 Test - Miscellaneous | Office | 37 | 23 | $24.36 | $901 |
| J0834 Injection, cosyntropin, 0.25 mg | Office | 37 | 37 | $18.97 | $702 |
By year: 2022 $137K for 22,625 services; 2023 $115K for 32,226 services; 2024 $103K for 30,209 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 12 | 11 | $9.52 | $114 |
Medicare prescription drug claims, 2024
In 2024, the drug Dany H Zayour prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,315 prescriptions and refills. In total Dany H Zayour wrote 6,905 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,315 | 3,422 | 355 | $13K |
| Synthroid Levothyroxine Sodium | 396 | 971 | 101 | $40K |
| Metformin Hcl Er Metformin Hcl | 289 | 781 | 91 | $2,061 |
| Liothyronine Sodium Generic | 286 | 718 | 89 | $11K |
| Tresiba Flextouch U-200 Insulin Degludec | 285 | 674 | 84 | $299K |
| Ozempic Semaglutide | 242 | 369 | 60 | $354K |
| Hydrocortisone Generic | 238 | 491 | 64 | $14K |
| Novolog Flexpen Insulin Aspart | 200 | 387 | 68 | $64K |
| Jardiance Empagliflozin | 196 | 370 | 41 | $210K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 159 | 332 | 46 | $24K |
| Mounjaro Tirzepatide | 148 | 190 | 33 | $194K |
| Methimazole Generic | 146 | 372 | 49 | $1,151 |
| Fiasp Flextouch Insulin Aspart (Niacinamide) | 140 | 230 | 37 | $136K |
| Metformin Hcl Generic | 134 | 359 | 39 | $1,335 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 114 | 295 | 52 | $13K |
Brand drugs: 3,748 claims; generic drugs: 2,839 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dany H Zayour $154K ($154K in general payments such as food, travel and fees) from 30 companies. The largest payer was Lilly USA, LLC with $83K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 99 | $83K |
| Novo Nordisk Inc NVO | 60 | $59K |
| Ascendis Pharma Endocrinology Inc ASND | 8 | $10K |
| Insulet Corporation PODD | 28 | $231 |
| Amgen Inc. AMGN | 16 | $229 |
| Medtronic, Inc. MDT | 5 | $212 |
| Xeris Pharmaceuticals, Inc. | 13 | $184 |
| Corcept Therapeutics CORT | 14 | $173 |
| Abbott Laboratories ABT | 8 | $171 |
| Dexcom, Inc. DXCM | 9 | $141 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.